Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Geron Corporation (GERN)

NASDAQ
Currency in USD
Disclaimer
4.3300
0.0000(0.00%)
Closed
After Hours
4.3300+0.0050(+0.1156%)
GERN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
4.18004.3350
52 wk Range
1.64005.3400
Prev. Close
4.33
Open
4.29
Day's Range
4.18-4.335
52 wk Range
1.64-5.34
Volume
7,336,494
Average Volume (3m)
8,788,001
1-Year Change
147.43%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
GERN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.3125
Upside
+68.8799%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

InvestingPro Research for Geron Corporation


Rytelo's Promise
Explore Geron's market position as Rytelo's launch metrics show early success, potentially reshaping the biopharmaceutical landscape
Financial Trajectory
Delve into Geron's financial performance, with FY2024 EPS at -$0.38 and FY2025 at -$0.20, reflecting typical biotech growth patterns
Strategic IP Moat
Discover how Geron's MoU patents could extend product exclusivity beyond 2035, potentially securing long-term market dominance
Analyst Optimism
Barclays maintains an Overweight rating with a $9.00 price target, signaling confidence in Geron's growth potential and market positioning

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Compare GERN to Peers and Sector

Metrics to compare
GERN
Peers
Sector
Relationship
P/E Ratio
−11.9x−3.0x−0.6x
PEG Ratio
-−0.040.00
Price/Book
8.5x3.1x2.6x
Price / LTM Sales
1,901.0x8.7x3.2x
Upside (Analyst Target)
61.7%308.6%43.9%
Fair Value Upside
Unlock21.5%7.8%Unlock

FAQ

What Is the Geron (GERN) Stock Price Today?

The Geron stock price today is 4.33.

What Stock Exchange Does Geron Trade On?

Geron is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Geron?

The stock symbol for Geron is "GERN."

What Is the Geron Market Cap?

As of today, Geron market cap is 2.61B.

What is Geron Earnings Per Share?

The Geron EPS is -0.361.

What Is the Next Geron Earnings Date?

Geron will release its next earnings report on 05 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.